Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

British Journal of Ophthalmology

Volumn 92, Issue 2, 2008, Pages 213-216

  Arevalo, J F ^a,h   Maia, M ^b   Flynn Jr , H W ^c   Saravia, M ^d   Avery, R L ^e   Wu, L ^f   Eid Farah, M ^b   Pieramici, D J ^e   Berrocal, M H ^g   Sanchez, J G ^a  

^a Clinica Oftalmologica Centro Caracas   (Venezuela)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSIDAD AUSTRAL   (Argentina)

^e California Retina Consultants and Research Foundation   (United States)

^f Instituto de Cirugia Ocular   (Costa Rica)

^g UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^h Clinica Oftalmologica   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETINA DETACHMENT; RETROSPECTIVE STUDY; VISION; VISUAL ACUITY; VITRECTOMY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 38949099070     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.127142     Document Type: Article

References (20)

1. Adamis AP, Miller JW, Bemal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-50.
2. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
3. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-45.
4. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005;139:476- 81.
5. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002;133:373-85.
6. Adamis AP, Altaweel M, Bressler NM, et al., Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-8.
7. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-8.
8. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352- 4.
9. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
10. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
11. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-84.
12. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270- 4.
13. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006:26:262-9.
14. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
15. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment for choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.
16. Kaufman SC, Ferris FL III, Seigel DG, et al. Factors associated with visual outcome after photocoagulation for diabetic retinopathy: Diabetic Retinopathy Study Report 13. Invest Ophthalmol Vis Sci 1989;30:23-8.
17. Fong DS, Ferris FL III, Davis MD, Chew EY, Early Treatment Diabetic Retinopathy Study Research Group. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Am J Ophthalmol 1999;127:137-41.
18. Spaide RF, Fisher Y. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-8.
19. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26:699-700.
20. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15.